lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   12 Trials   12 Trials   1286 News 


«12...3456789101112131415»
  • ||||||||||  olanzapine / Generic mfg., fluoxetine / Generic mfg.
    Review, Journal:  Pharmacologic Treatment of Eating Disorders. (Pubmed Central) -  Feb 7, 2020   
    Binge eating disorder can be treated with antidepressants, with medications that diminish appetite, or with lisdexamfetamine. Anorexia nervosa does not generally respond to medications, although recent evidence supports modest weight restoration benefits from olanzapine.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda, dasotraline (SEP-225289) / Sumitomo Dainippon
    Review, Journal:  Investigational drugs for the treatment of binge eating disorder (BED): an update. (Pubmed Central) -  Dec 27, 2019   
    Despite these advances, pharmacological trials in BED have numerous challenges that must be overcame. For most compounds studied, larger and more definitive trials is a high priority.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment change, Trial termination:  LEIA: Lisdexamfetamine's Effect In ADHD in the Brain and Cognition (clinicaltrials.gov) -  Dec 26, 2019   
    P4,  N=6, Terminated, 
    For most compounds studied, larger and more definitive trials is a high priority. N=13 --> 6 | Completed --> Terminated; Lack of enrollment
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Journal:  A Case of Sedation Secondary to a Trial of Lisdexamfetamine. (Pubmed Central) -  Dec 20, 2019   
    Across gender and age, participants exhibited comparable clinical characteristics and responses to dose-optimized LDX compared with placebo. No abstract available
  • ||||||||||  Ritalin (methylphenidate tablet) / Generic mfg., modafinil / Generic mfg., bupropion / Generic mfg.
    Comparative Efficacy and Tolerability of Adhd Medications in children/adolescents and adults: Systematic Review and Network Meta-Analysis  (Thurgood Marshall Ballroom) -  Dec 12, 2019 - Abstract #APSARD2020APSARD_122;    
    It is important appreciate that, rather than a guideline per se, our network meta-analysis is meant to provide evidence that should be taken into account in future guidelines, alongside other considerations (e.g., cost-effectiveness). Finally, I will present ongoing projects based on the same dataset: placebo effect, comparison of medications on individual adverse effects, and individual patient network meta-analysis, which should allow to move from results at the group level to findings that will be able to inform decision-making at the individual patient level.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Review, Journal:  Treatment of eating disorders with concurrent ADHD symptoms: knowledge, knowledge gaps and clinical implications (Pubmed Central) -  Dec 6, 2019   
    For patients diagnosed with ADHD, treatment with stimulants can be tested and evaluated for both eating disorders and ADHD symptoms. While there is evidence that lisdexamfetamine reduces symptoms of binge eating disorder, rigorous studies evaluating ADHD treatment, including medication, for bulimia nervosa are still missing.
  • ||||||||||  olanzapine / Generic Mfg.
    Review, Journal:  Recent advances in therapies for eating disorders. (Pubmed Central) -  Oct 29, 2019   
    Case study and pilot data are beginning to show limited support for neuromodulatory interventions targeting brain regions thought to be involved in eating disorders. This review summarizes treatment developments over the last several years and points towards future directions for the field.
  • ||||||||||  modafinil / generics
    SLEEP AID AND STIMULANT USE AMONG NURSES IN AN ACADEMIC MEDICAL CENTER (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_3954;    
    While melatonin and caffeine are options to assist with sleep and wake in certain circadian rhythm sleep disorders, a considerable amount of prescription strength sleep aids and stimulants were also utilized by nurses.Clinical Implications:Chronic use of sleep aids and stimulants may be associated with long term adverse health effects. Treatment of modifiable factors such as workplace demands, rotational shift work and undiagnosed sleep disorders may minimize use of both non-prescription and prescription sleep aids and stimulants among nurses.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion, Trial completion date:  Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT (clinicaltrials.gov) -  Sep 23, 2019   
    P2,  N=86, Completed, 
    Treatment of modifiable factors such as workplace demands, rotational shift work and undiagnosed sleep disorders may minimize use of both non-prescription and prescription sleep aids and stimulants among nurses. Recruiting --> Completed | Trial completion date: Dec 2019 --> Jan 2019
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (Pubmed Central) -  Sep 8, 2019   
    Treatment with lisdexamfetamine potentiates affective encoding in amygdala, purportedly via catecholaminergic mechanisms, but functionally disconnects the amygdala from inferior frontal regions that encode behavioral significance-resulting in reduced emotional bias of cognitive control. Pinpointing the neurophysiologic underpinnings of therapeutic improvement with lisdexamfetamine represents a first step in developing targeted approaches to treatment of ADHD.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) -  Aug 7, 2019   
    P4,  N=40, Recruiting, 
    New research should be funded urgently to assess long-term effects of these drugs. Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Vyvanse (Twitter) -  Jul 30, 2019   
  • ||||||||||  methylphenidate tablet / generics, modafinil / generics, tetrabenazine / generics
    Journal:  The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding. (Pubmed Central) -  Jul 19, 2019   
    ...Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage...(S)-CE-123 ((S)-5-((benzhydrylsulfinyl) methyl)thiazole) is a recently developed analog of modafinil with the biochemical characteristics of an atypical DA transport blocker...In summary, (S)-CE-123 has the behavioral and neurochemical profile of a compound that can block DA transport, reverse the effort-related effects of tetrabenazine, and increase selection of high-effort progressive ratio responding. This suggests that (S)-CE-123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Phase classification, Trial termination:  Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence (clinicaltrials.gov) -  Jul 15, 2019   
    P1,  N=43, Terminated, 
    This suggests that (S)-CE-123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans. Phase classification: P1/2 --> P1 | Completed --> Terminated; Low enrollment
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder (Grand Ballroom Foyer) -  Jul 14, 2019 - Abstract #CADDRAADHD2019CADDRA_47;    
    In preschool-aged children with ADHD, LDX treatment was generally well tolerated andreduced ADHD symptoms, consistent with observations in children aged 6–17 years. Based onthese findings, a starting LDX dose as low as 5 mg in phase 3 studies in preschool-aged children issupported.
  • ||||||||||  NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
    Trial primary completion date:  ADAPT: ADHD Medication and Predictors of Treatment Outcome (clinicaltrials.gov) -  Jul 9, 2019   
    P=N/A,  N=2000, Enrolling by invitation, 
    Both stimulants led to performance that exceeded the average DMV driver, improvedEF over routine care, and resulted in similar driving responses at 1, 9, 12 and 15 hours post-dose. Trial primary completion date: Mar 2019 --> Dec 2020
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Review, Journal:  Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. (Pubmed Central) -  May 18, 2019   
    BED and NES are also associated with higher risk of psychopathology, including mood, anxiety, and sleep problems, than those of similar weight status without disordered eating. Treatments are available, including cognitive behavior therapy (CBT), interpersonal psychotherapy, lisdexamfetamine, and selective serotonin reuptake inhibitors (SSRIs) for BED; and CBT, SSRIs, progressive muscle relaxation, and bright light therapy for NES.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial initiation date:  Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (clinicaltrials.gov) -  May 18, 2019   
    P3,  N=80, Recruiting, 
    Treatments are available, including cognitive behavior therapy (CBT), interpersonal psychotherapy, lisdexamfetamine, and selective serotonin reuptake inhibitors (SSRIs) for BED; and CBT, SSRIs, progressive muscle relaxation, and bright light therapy for NES. Initiation date: Mar 2019 --> Aug 2019